Bcl-2 antagonists: A proof of concept for CLL therapy

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1384-1394

  Balakrishnan, Kumudha ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; BH3 mimetics; CLL; Gossypol; Natural products

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; APOGOSSYPOL; APOGOSSYPOLONE; BI 79D10; BI 97C1; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUDARABINE; GEMINX; GOSSYPOL; GOSSYPOL DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HOMOHARRINGTONINE; INTERLEUKIN 24; ISOSORBIDE; NAVITOCLAX; OBATOCLAX; PLACEBO; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RITUXIMAB; ROSCOVITINE; SABUTOCLAX; SORAFENIB; TOPOTECAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; B CELL LYMPHOMA; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FOLLICULAR LYMPHOMA; GOSSYPIUM HIRSUTUM; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALE INFERTILITY; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84884814110     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0002-4     Document Type: Review

References (124)

1. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72-79
2. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646-662
3. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327
4. Stahelin H (1973) Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 9:215-221
5. Harvey AL (1999) Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol Sci 20:196-198
6. Powell RG, Weisleder D, Smith CR, Jr., Rohwedder WK (1970) Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett 815-818
7. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M (1996) Treatment of myelogenous leukemia: current status and investigational options. Blood 87:3069-3081
8. Kelland LR (2000) Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 9:2903-2911
9. Christian MC, Pluda JM, Ho PT, Arbuck SG, Murgo AJ, Sausville EA (1997) Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Semin Oncol 24:219-240
10. Meijer L, Raymond E (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36:417-425
11. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM (1987) Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50:119-131
12. Jd E (1958) Total synthesis of gossypol. J Am Chem Soc 80:3798-3799
13. Adams RMR, Geissman TA, Butterbaugh DJ, Kirkpatrick EC (1938) Structure of gossypol. An interpretation of its reaction. J Am Chem Soc 60:2193-2203
14. Wu D (1989) An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs 38:333-341
15. Waites GM, Wang C, Griffin PD (1998) Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int J Androl 21:8-12
16. Coutinho EM (2002) Gossypol: a contraceptive for men. Contraception 65:259-263
17. Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B et al (2003) Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 66:93-103
18. Zhang M, Liu H, Tian Z, Griffith BN, Ji M, Li QQ (2007) Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci 80:767-774
19. Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, O'Connell KM et al (2004) In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10:7757-7763
20. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K et al (2001) Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 66:239-248
21. Tso WW, Lee CS (1982) Lactate dehydrogenase-X: an isozyme particularly sensitive to gossypol inhibition. Int J Androl 5:205-209
22. Teng CS (1995) Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes. Contraception 52:389-395
23. Wang Y, Rao PN (1984) Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro. Cancer Res 44:35-38
24. Ligueros M, Jeoung D, Tang B, Hochhauser D, Reidenberg MM, Sonenberg M (1997) Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br J Cancer 76:21-28
25. Shidaifat F, Canatan H, Kulp SK, Sugimoto Y, Zhang Y, Brueggemeier RW et al (1997) Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Res 17:1003-1009
26. Hou DX, Uto T, Tong X, Takeshita T, Tanigawa S, Imamura I et al (2004) Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch Biochem Biophys 428:179-187
27. Chang JS, Hsu YL, Kuo PL, Chiang LC, Lin CC (2004) Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol 31:716-722
28. Lei X, Chen Y, Du G, Yu W, Wang X, Qu H et al (2006) Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J 20:2147-2149
29. Moon DO, Kim MO, Lee JD, Kim GY (2008) Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells. Cancer Lett 264:192-200
30. Lian J, Wu X, He F, Karnak D, Tang W, Meng Y et al (2011) A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 18:60-71
31. Gao P, Bauvy C, Souquere S, Tonelli G, Liu L, Zhu Y et al (2010) The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem 285:25570-25581
32. Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA et al (1993) Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76:1019-1024
33. Stein RC, Joseph AE, Matlin SA, Cunningham DC, Ford HT, Coombes RC (1992) A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 30:480-482
34. Bushunow P, Reidenberg MM, Wasenko J, Winfield J, Lorenzo B, Lemke S et al (1999) Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 43:79-86
35. Reed JC, Pellecchia M (2005) Apoptosis-based therapies for hematologic malignancies. Blood 106:408-418
36. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M (2003) Discovery, characterization, and structure-Activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46:4259-4264
37. Meng Y, Li Y, Li J, Li H, Fu J, Liu Y et al (2007) (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk Lymphoma 48:2204-2212
38. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V (2008) Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112:1971-1980
39. Zhai D, Jin C, Satterthwait AC, Reed JC (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13:1419-1421
40. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE (2005) (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 4:23-31
41. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D et al (2004) Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 11:389-395
42. Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD et al (1998) Testicular degeneration in Bclw-deficient mice. Nat Genet 18:251-256
43. Johnsen O, Mas Diaz J, Eliasson R (1982) Gossypol; a potent inhibitor of human sperm acrosomal proteinase. Int J Androl 5:636-640
44. Qiu J, Levin LR, Buck J, Reidenberg MM (2002) Different pathways of cell killing by gossypol enantiomers. Exp Biol Med (Maywood) 227:398-401
45. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J et al (2006) Structure-based design of potent small-molecule inhibitors of anti-Apoptotic Bcl-2 proteins. J Med Chem 49:6139-6142
46. Balakrishnan K, Burger JA, Wierda WG, Gandhi V (2009) AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113:149-153
47. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al (2009) Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113:4403-4413
48. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96:2655-2663
49. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N et al (2002) Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 100:1795-1801
50. Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J et al (2008) Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111:5350-5358
51. Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C et al (2012) Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 287:68-80
52. Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ et al (2011) A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 6:1757-1760
53. Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT et al (2011) Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 6:781-785
54. Wei J, Rega MF, Kitada S, Yuan H, Zhai D, Risbood P et al (2009) Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists. Cancer Lett 273:107-113
55. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC (2008) Bcl-2 antagonist apogossypol (NSC736630) displays single-Agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111:3211-3219
56. Jia L, Coward LC, Kerstner-Wood CD, Cork RL, Gorman GS, Noker PE et al (2008) Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother Pharmacol 61:63-73
57. Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J et al (2009) Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 8:904-913
58. Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J et al (2009) Apogossypol derivatives as pan-Active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 52:4511-4523
59. Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK et al (2011) Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A 108:8785-8790
60. Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA et al (2012) Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J Cell Physiol 227:2145-2153
61. Gilbert NE, O'Reilly JE, Chang CJ, Lin YC, Brueggemeier RW (1995) Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci 57:61-67
62. Dao VT, Dowd MK, Martin MT, Gaspard C, Mayer M, Michelot RJ (2004) Cytotoxicity of enantiomers of gossypol Schiff's bases and optical stability of gossypolone. Eur J Med Chem 39:619-624
63. Zhan Y, Jia G, Wu D, Xu Y, Xu L (2009) Design and synthesis of a gossypol derivative with improved antitumor activities. Arch Pharm (Weinheim) 342:223-229
64. Mohammad RM YD, Chen B, Aboukameel A, Chen J, Nikolovska-Coleska Z, Al-Katib A, Wang S (2006) ApoG2, a potent, non-toxic small-molecule inhibitor of Bcl-2 family: a preclinical trial in lymphoma Proc Amer Assoc Cancer Res;Abstract #1335
65. Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A et al (2008) Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer 7:20
66. Sun J, Li ZM, Hu ZY, Lin XB, Zhou NN, Xian LJ et al (2008) ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells. Anticancer Drugs 19:967-974
67. Balakrishnan K, Aggarwal S, Wierda W, Gandhi V (2013) Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma 54:1097-1100
68. Sun Y, Wu J, Aboukameel A, Banerjee S, Arnold AA, Chen J et al (2008) Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther 7:1418-1426
69. Hu ZY, Sun J, Zhu XF, Yang D, Zeng YX (2009) ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. J Transl Med 7:74
70. Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B et al (2010) Synthesis and biological evaluation of Apogossypolone derivatives as pan-Active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 53:8000-8011
71. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104:19512-19517
72. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK (2007) Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109:5430-5438
73. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z et al (2008) Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68:3413-3420
74. Campas C, Cosialls AM, Barragan M, Iglesias-Serret D, Santidrian AF, Coll-Mulet L et al (2006) Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 34:1663-1669
75. Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M, Villamor N, Montserrat E et al (2008) BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 22:1712-1720
76. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D (2007) The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109:4441-4449
77. Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P et al (2010) Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 10:903-917
78. Huang S, Okumura K, Sinicrope FA (2009) BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 15:150-159
79. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H et al (2010) The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 6:976-978
80. Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A et al (2009) BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 76:327-341
81. Rahmani M, Aust MM, Attkisson E, Williams DC, Jr (2012) Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 anti-Apoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood
82. Martinez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, Gonzalez-Bonilla C, Bonavida B et al (2011) Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle 10:2792-2805
83. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD et al (2008) A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14:8295-8301
84. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ et al (2009) Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113:299-305
85. Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N et al (2011) A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 74:481-485
86. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J et al (2012) Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119:2171-2172
87. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681
88. Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM (2010) Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 16:4217-4225
89. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ et al (2009) Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16:1030-1039
90. Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A et al (2011) ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res 17:5973-5981
91. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103:14907-14912
92. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388
93. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112-121
94. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P et al (2008) A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15:820-830
95. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA et al (2007) ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21:1549-1560
96. Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maiga S et al (2011) ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 118:3901-3910
97. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM et al (2007) Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110:2057-2066
98. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111:2300-2309
99. Chen S, Dai Y, Pei XY, Grant S (2009) Bim up-regulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL and Mcl-1. Mol Cell Biol
100. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer cell 10:389-399
101. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26:3972-3979
102. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al (2011) SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471:104-109
103. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463:103-107
104. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L et al (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112:2906-2916
105. Chen S, Dai Y, Pei XY, Grant S (2009) Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 29:6149-6169
106. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD et al (2009) The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23:2034-2041
107. Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A et al (2008) ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 140:181-190
108. Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67:782-791
109. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M (2012) Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer 118:1023-1031
110. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM et al (2012) Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res 18:487-498
111. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, et al (2012) Bcl-2, Bcl-xL and Bcl-w are not equivalent targets of ABT-737 and Navitoclax (ABT-263) in lymphoid and leukemic cells. Blood
112. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428
113. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D et al (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14:3268-3277
114. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M et al (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7:3265-3274
115. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29:909-916
116. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al (2010) Navitoclax, a targeted high-Affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11:1149-1159
117. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al (2012) Phase II study of single-Agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res
118. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-496
119. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208
120. Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W et al (2012) Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 287:10224-10235
121. Wei J, Stebbins JL, Kitada S et al (2010) BI-97C1, an optically pure Apogossypol derivative as pan-Active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 53(10):4166-4176
122. Rudin CM, Hann CL, Garon EB et al (2012) Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. Clin Cancer Res 18(11):3163-3169
123. Stewart ML, Fire E, Keating AE, Walensky LD (2010) The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 6(8):595-601
124. Lee EF, Czabotar PE, van Delft MF, et al (2008) A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 180(2):341-355